Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Inspira Technologies Oxy B.H.N. Ltd. (IINNW) provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files annual reports on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings often include or reference press releases that describe product milestones, regulatory clearances, purchase orders, government-related discussions, and financing transactions.
Through its Form 6-K submissions, Inspira reports developments such as FDA 510(k) clearance and Israeli AMAR certification for the INSPIRA ART100 cardiopulmonary bypass system, government and institutional purchase orders for ART100 systems, and updates on the HYLA real-time blood sensor’s progress toward U.S. Food and Drug Administration submission. Other 6-K filings have covered matters like sales agreement amendments, private placements, and the activation of consulting firms to support business initiatives.
On this page, users can review how Inspira describes its INSPIRA ART platform, ART100 system, VORTX oxygenation technology, INSPIRA Cardi-ART device, and HYLA blood sensor within official filings. These documents outline the development status of each technology, including statements that certain products are still being designed and developed, have not been tested or used in humans, and are not yet approved by regulatory entities.
Stock Titan enhances access to these filings with tools that surface key sections and context from lengthy reports, helping readers quickly locate information on topics such as product regulatory status, capital raising activities, and material agreements. Real-time updates from EDGAR ensure that new Inspira Technologies filings, including future 6-Ks and other forms, appear here as they are submitted, alongside any disclosed information on warrants, purchase orders, or other corporate actions.
Inspira Technologies Oxy B.H.N. Ltd. disclosed a press release dated September 2, 2025 announcing that a top U.S. Honor Roll hospital has expanded clinical use of the company’s INSPIRA™ ART100 system to include lung transplant procedures. The filing reproduces the press release and is signed by Dagi Ben-Noon, Chief Executive Officer. The statement highlights broader clinical adoption of the ART100 device but does not provide revenue, patient counts, contract terms, or trial results in this filing.
Inspira Technologies Oxy B.H.N. Ltd. reports that it has received U.S. patent approval for its ART500 core technology. The company describes this patent in its press release title as a key asset that could position it to address an estimated $20 billion market, underscoring management’s view of the technology’s commercial potential.
The filing also notes that the first, second, and fourth paragraphs of the press release and its “Forward-Looking Statements” section are incorporated by reference into Inspira’s existing shelf and equity compensation registration statements on Forms F-3 and S-8. This means the patent-related disclosure and related forward-looking commentary are now formally part of those registration documents.
Inspira Technologies Oxy B.H.N. Ltd. announced a binding purchase order from a government customer for $27 million of ART100 systems, with the company stating that full payment will be received in 2025. The notice, filed as a Form 6-K and dated August 19, 2025, is signed by Chief Executive Officer Dagi Ben-Noon. The release communicates a material commercial win and a confirmed cash inflow timing without providing further operational or delivery details.